Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Ocular Therapeutix Inc Company Overview 4
Ocular Therapeutix Inc Company Snapshot 4
Ocular Therapeutix Inc Pipeline Products and Ongoing Clinical Trials Overview 4
Ocular Therapeutix Inc – Pipeline Analysis Overview 7
Ocular Therapeutix Inc – Key Facts 7
Ocular Therapeutix Inc – Major Products and Services 8
Ocular Therapeutix Inc Pipeline Products by Development Stage 9
Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status 11
Ocular Therapeutix Inc Pipeline Products Overview 12
DEXTENZA 12
DEXTENZA Product Overview 12
OTX-IVT 13
OTX-IVT Product Overview 13
OTX-MP 14
OTX-MP Product Overview 14
OTX-TIC 15
OTX-TIC Product Overview 15
OTX-TIC Clinical Trial 16
OTX-TKI 17
OTX-TKI Product Overview 17
OTX-TP 18
OTX-TP Product Overview 18
OTX-TP Clinical Trial 19
Ocular Therapeutix Inc – Key Competitors 20
Ocular Therapeutix Inc – Key Employees 21
Ocular Therapeutix Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Ocular Therapeutix Inc, Recent Developments 23
Jul 19, 2018: Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for DEXTENZA 23
Jun 29, 2018: Ocular Therapeutix Announces NDA Resubmission of DEXTENZA 23
May 03, 2018: Ocular Therapeutix Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC (travoprost intracameral implant) for the Treatment of Glaucoma and Ocular Hypertension 23
Apr 09, 2018: Ocular Therapeutix to Present Data at the American Society of Cataract and Refractive Surgery Symposium 24
Mar 08, 2018: Ocular Therapeutix Reports Fourth Quarter and Year End 2017 Financial Results and Business Update 24
Jan 08, 2018: Ocular Therapeutix Announces Kevin Hanley as Senior Vice President, Technical Operations and Naymisha Patel as Vice President of Quality 26
Dec 22, 2017: Ocular Therapeutix Provides Legal Update 26
Nov 07, 2017: Ocular Therapeutix Reports Third Quarter 2017 Financial Results and Provides Corporate Update 27
Sep 25, 2017: Ocular Therapeutix Appoints Donald Notman as Chief Financial Officer 28
Sep 08, 2017: Ocular Therapeutix Appoints Michael Goldstein, M.D., M.B.A., as Chief Medical Officer 28
Appendix 30
Methodology 30
About GlobalData 33
Contact Us 33
Disclaimer 33
Ocular Therapeutix Inc Pipeline Products and Ongoing Clinical Trials Overview 4
Ocular Therapeutix Inc Pipeline Products by Equipment Type 5
Ocular Therapeutix Inc Pipeline Products by Indication 6
Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status 6
Ocular Therapeutix Inc, Key Facts 7
Ocular Therapeutix Inc, Major Products and Services 8
Ocular Therapeutix Inc Number of Pipeline Products by Development Stage 9
Ocular Therapeutix Inc Pipeline Products Summary by Development Stage 10
Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status 11
Ocular Therapeutix Inc Ongoing Clinical Trials Summary 11
DEXTENZA - Product Status 12
DEXTENZA - Product Description 12
OTX-IVT - Product Status 13
OTX-IVT - Product Description 13
OTX-MP - Product Status 14
OTX-MP - Product Description 14
OTX-TIC - Product Status 15
OTX-TIC - Product Description 15
OTX-TIC - To Evaluate the Safety, Efficacy, Durability, and Tolerability of OTX-TIC in Patients with Primary Open-angle Glaucoma or Ocular Hypertension 16
OTX-TKI - Product Status 17
OTX-TKI - Product Description 17
OTX-TP - Product Status 18
OTX-TP - Product Description 18
OTX-TP - Non-significant Risk Feasibility Study to Assess Retention and Replacement of the OTX Punctum Plug 19
Ocular Therapeutix Inc, Key Employees 21
Ocular Therapeutix Inc, Other Locations 22
Glossary 32
List of Figures
Ocular Therapeutix Inc Pipeline Products by Equipment Type 5
Ocular Therapeutix Inc Pipeline Products by Development Stage 9
Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status 11